CL2025000120A1 - Compuestos de piridinona sustituida como inhibidores de cbl-b. - Google Patents

Compuestos de piridinona sustituida como inhibidores de cbl-b.

Info

Publication number
CL2025000120A1
CL2025000120A1 CL2025000120A CL2025000120A CL2025000120A1 CL 2025000120 A1 CL2025000120 A1 CL 2025000120A1 CL 2025000120 A CL2025000120 A CL 2025000120A CL 2025000120 A CL2025000120 A CL 2025000120A CL 2025000120 A1 CL2025000120 A1 CL 2025000120A1
Authority
CL
Chile
Prior art keywords
cbl
inhibitors
compounds
pyridinone compounds
substituted pyridinone
Prior art date
Application number
CL2025000120A
Other languages
English (en)
Inventor
Chinnapattu Murugan
Chaudhari Sachin
Gowda Nagaraj
Das Sanjib
Iyer Pravin
Waghmare Nayan
Shelke Sandeep
Gavhane Balasaheb
Saini Jagmohan
Kadam Sheetal
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of CL2025000120A1 publication Critical patent/CL2025000120A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a compuestos de fórmula (I) y sales farmacéuticamente aceptables de estos, que son útiles como inhibidores de CBL-b, procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos y el uso de los compuestos o las composiciones en el tratamiento o la prevención de diversas enfermedades, afecciones y/o trastornos mediados por CBL-b.
CL2025000120A 2022-08-16 2025-01-15 Compuestos de piridinona sustituida como inhibidores de cbl-b. CL2025000120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202221046493 2022-08-16

Publications (1)

Publication Number Publication Date
CL2025000120A1 true CL2025000120A1 (es) 2025-06-13

Family

ID=87929171

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025000120A CL2025000120A1 (es) 2022-08-16 2025-01-15 Compuestos de piridinona sustituida como inhibidores de cbl-b.

Country Status (13)

Country Link
EP (1) EP4573085A1 (es)
JP (1) JP2025525947A (es)
KR (1) KR20250050018A (es)
CN (1) CN119546587A (es)
AU (1) AU2023326220A1 (es)
CA (1) CA3258870A1 (es)
CL (1) CL2025000120A1 (es)
CO (1) CO2025003090A2 (es)
CU (1) CU20250003A7 (es)
IL (1) IL318955A (es)
MX (1) MX2025001865A (es)
PE (1) PE20251389A1 (es)
WO (1) WO2024038378A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025076299A1 (en) * 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025214476A1 (zh) * 2024-04-11 2025-10-16 北京诺诚健华医药科技有限公司 Cbl-b抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
WO2021021761A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4034141A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
WO2022169998A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Amides as cbl-b inhibitors

Also Published As

Publication number Publication date
CA3258870A1 (en) 2024-02-22
CO2025003090A2 (es) 2025-03-27
KR20250050018A (ko) 2025-04-14
MX2025001865A (es) 2025-04-02
JP2025525947A (ja) 2025-08-07
CU20250003A7 (es) 2025-09-01
AU2023326220A1 (en) 2025-02-20
PE20251389A1 (es) 2025-05-22
IL318955A (en) 2025-04-01
WO2024038378A1 (en) 2024-02-22
CN119546587A (zh) 2025-02-28
EP4573085A1 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2024001964A1 (es) Compuestos para la inhibición de nlrp3 y usos de estos
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
JOP20240165A1 (ar) مشتقات بيبريدينيل سبيرو سيكليك كمثبطات عامل مكمل b واستخداماتها
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
MX387232B (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
CL2021000282A1 (es) Inhibidores de ckd8/19
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
UY38133A (es) Nuevos inhibidores de cdk8/19
AR069569A1 (es) Derivados de benzoxazina, un intermediario para su preparacion, una composicion farmaceutica que los comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de renina.
BR112023004214A2 (pt) Métodos de tratamento de doenças ou condições mediadas por pde iv
CO2024015920A2 (es) Forma cristalina de un inhibidor de fosfodiesterasa 4 (pde4)
AR134411A1 (es) Compuestos de uracilo
AR130051A1 (es) Inhibidores de calicreína plasmática